LYMPHOMA NON-HODGKIN

This study tested an oral drug called LOXO-305 in 87 Chinese adults with lymphoma or chronic lymphocytic leukemia who had already received standard treatments. The goal was to see how safe and effective the drug is. Participation could last up to four years. The study is now comp…

This early-stage study tested an experimental drug called JNJ-75348780 in 147 people with relapsed or refractory B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goal wa…

This early-phase study tested a new drug called LP-118 in 68 people with advanced solid tumors or lymphomas that had stopped responding to standard treatments. The goal was to find a safe dose and see how the body processes the drug. LP-118 works by blocking certain proteins that…

This study tested a combination of two drugs, favezelimab and pembrolizumab, in 137 people with Hodgkin lymphoma and other B-cell blood cancers. The goal was to see if the combo is safe and can shrink tumors. Participants received the drugs alone or together, and researchers moni…

This study tested an experimental drug called mosunetuzumab, given alone or with another drug (atezolizumab), in 713 people with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia that had come back or stopped responding to prior treatments. The goal was to find the safe…

This study tested whether replacing a standard transplant drug (cyclophosphamide) with a different drug (bendamustine) could make half-matched bone marrow transplants safer for people with blood cancers like leukemia and lymphoma. About 50 patients took part. The goal was to redu…

This study tested whether adding the drug copanlisib to standard rituximab therapy helps people with relapsed indolent B-cell non-Hodgkin's lymphoma live longer without their cancer getting worse. About 458 adults who had already received at least one prior treatment took part. T…

This early-stage study tested a combination of two immunotherapy drugs, relatlimab and nivolumab, in 5 children and young adults whose Hodgkin or non-Hodgkin lymphoma had returned or stopped responding to standard treatments. The main goals were to check safety, find the right do…

This study looked back at 30 people with HIV who had already received CAR T-cell therapy for certain blood cancers. Researchers collected standard medical data to see what side effects occurred and how the immune system changed over time. The goal was to learn more about safety a…

This study looked at the genes of over 1,300 people with blood cancers like lymphoma, leukemia, and multiple myeloma. The goal was to find genetic patterns that could explain why some patients respond well to treatment while others do not. Researchers used stored tissue samples a…